RNA Therapeutics: The Evolving Landscape of RNA Therapeutics
Editat de Paloma H. Giangrande, Vittorio de Franciscis, John J. Rossien Limba Engleză Paperback – 13 apr 2022
Later sections discuss delivery technologies, remaining hurdles in research and translation, the therapy development process from the lab to the clinic, and novel RNA-based therapies currently in development.
- Features leading experts in the field of RNA therapeutics, spanning all classes of RNA therapies
- Provides a detailed examination of approved RNA therapies and lessons learned from failed therapeutics
- Covers all aspects of therapeutic discovery and preclinical development, as well as clinical translation, manufacturing and regulatory aspects
Preț: 848.01 lei
Preț vechi: 1107.72 lei
-23% Nou
Puncte Express: 1272
Preț estimativ în valută:
162.30€ • 168.79$ • 135.81£
162.30€ • 168.79$ • 135.81£
Carte tipărită la comandă
Livrare economică 08-22 martie
Livrare express 08-14 februarie pentru 103.68 lei
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9780128215951
ISBN-10: 012821595X
Pagini: 472
Ilustrații: 100 illustrations (50 in full color)
Dimensiuni: 191 x 235 x 32 mm
Greutate: 0.81 kg
Editura: ELSEVIER SCIENCE
ISBN-10: 012821595X
Pagini: 472
Ilustrații: 100 illustrations (50 in full color)
Dimensiuni: 191 x 235 x 32 mm
Greutate: 0.81 kg
Editura: ELSEVIER SCIENCE
Cuprins
SECTION 1 The world of RNA therapeutics: Available RNA tools to modulate cellular processes
1. Targeting chromatin: Transcriptional gene activation (saRNA)
2. Argonaute and TNRC6, partners in RNAi
3. Targeted RNA therapeutics for treatment of cancer and immunomodulation
4. Extrahepatic delivery of RNA to immune cells
SECTION 2 Learning from history
5. Aptamer-based protein inhibitors
6. Lessons learned from developing an oligonucleotide drug for a rare disease
SECTION 3 Delivery
7. Nucleoside modifications of in vitro transcribed mRNA to reduce immunogenicity and improve translation of prophylactic and therapeutic antigens
8. SOMAmer reagents and the SomaScan platform: Chemically modified aptamers and their applications in therapeutics, diagnostics, and proteomics
SECTION 4 From bench to bedside
9. CMC and regulatory aspects of oligonucleotide therapeutics
10. CMC: Regulatory landscape
11. CMC and manufacturing
SECTION 5 From bench to bedside
12. RNA delivery for cancer gene therapy
13. Combinatorial RNA therapies in cancer immunotherapy: Challenges and directions
1. Targeting chromatin: Transcriptional gene activation (saRNA)
2. Argonaute and TNRC6, partners in RNAi
3. Targeted RNA therapeutics for treatment of cancer and immunomodulation
4. Extrahepatic delivery of RNA to immune cells
SECTION 2 Learning from history
5. Aptamer-based protein inhibitors
6. Lessons learned from developing an oligonucleotide drug for a rare disease
SECTION 3 Delivery
7. Nucleoside modifications of in vitro transcribed mRNA to reduce immunogenicity and improve translation of prophylactic and therapeutic antigens
8. SOMAmer reagents and the SomaScan platform: Chemically modified aptamers and their applications in therapeutics, diagnostics, and proteomics
SECTION 4 From bench to bedside
9. CMC and regulatory aspects of oligonucleotide therapeutics
10. CMC: Regulatory landscape
11. CMC and manufacturing
SECTION 5 From bench to bedside
12. RNA delivery for cancer gene therapy
13. Combinatorial RNA therapies in cancer immunotherapy: Challenges and directions